On April 27, 2022 Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, reported that its abstract highlighting initial data from patients in Cohort 1 of the ongoing Phase 2 CRESTONE study was selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held June 3-7, 2022 in Chicago (Press release, Elevation Oncology, APR 27, 2022, View Source;utm_medium=rss&utm_campaign=elevation-oncology-announces-initial-data-from-phase-2-crestone-study-of-seribantumab-selected-for-oral-presentation-at-asco-2022 [SID1234613030]). CRESTONE is a tumor-agnostic clinical trial evaluating seribantumab in patients with solid tumors that harbor an NRG1 fusion and have progressed after at least one prior line of standard therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe seribantumab has the potential to be a best-in-class and differentiated therapy for patients with tumors that harbor NRG1 gene fusions, and we are pleased to have the opportunity to share data with the medical community through an oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting," said Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology. "These genomically defined patients are particularly underserved with no approved targeted therapies currently available. We look forward to presenting initial clinical data from our ongoing Phase 2 clinical trial evaluating seribantumab’s ability to address the underlying drivers of tumor growth in this difficult-to-treat patient population."
Details for the ASCO (Free ASCO Whitepaper) 2022 oral presentation are as follows:
Title: CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions
Authors: Daniel Carrizosa, Levine Cancer Institute, Atrium Health
Abstract Number: 3006
Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Date and Time: Tuesday, June 7, 2022, 9:45AM-12:45PM CT
The abstract will be published by ASCO (Free ASCO Whitepaper) on May 26, 2022 at 5:00 pm ET. The abstract and a broadcast of the oral presentation can be accessed on the ASCO (Free ASCO Whitepaper) 2022 website at conferences.asco.org/am. Copies of these materials will also be available on the Elevation Oncology website at elevationoncology.com/resources/publications following completion of the live presentation.
About Seribantumab and NRG1 Gene Fusions
Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3). HER3 is traditionally activated through binding of its primary ligand, neuregulin-1 (NRG1). The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner protein to create chimeric NRG1 "fusion proteins". The NRG1 fusion protein is often also able to activate the HER3 pathway, leading to unregulated cell growth and proliferation. Importantly, NRG1 gene fusions are predominantly mutually exclusive with other known genomic driver mutations and are considered a unique oncogenic driver event associated with tumor cell survival.
NRG1 fusions have been identified in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, neuroendocrine, cholangiocarcinomas, and sarcomas. In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion and destabilized the entire ERBB family signaling pathway including the activation of HER2, EGFR, and HER4. In addition to extensive nonclinical characterization and testing, seribantumab has been administered to over 800 patients across twelve Phase 1 and 2 studies, both as a monotherapy and in combination with various anti-cancer therapies. Seribantumab is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 fusion.
About the Phase 2 CRESTONE Study
Clinical Study of Response to Seribantumab in Tumors with Neuregulin-1 (NRG1) Fusions. CRESTONE is a Phase 2 tumor-agnostic "basket trial" of seribantumab in patients with solid tumors that harbor an NRG1 fusion and have progressed after at least one prior line of standard therapy. The primary objective of the study is to describe the anti-tumor activity and safety of seribantumab as a monotherapy specifically in patients whose solid tumor is uniquely driven by an NRG1 gene fusion. CRESTONE offers a clinical trial opportunity for patients with advanced solid tumors who have not responded or are no longer responding to treatment. Patients are encouraged to talk to their doctor about genomic testing of their tumor. CRESTONE is open and enrolling today in the United States, Australia, and Canada. For more information visit www.NRG1fusion.com.